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Background: Both transcriptional factor Ets-1 and integrin αvβ6 play an important role in the development and
progression of cancer. The aim of our study was to investigate the expression of Integrin αvβ6 and Ets-1, two
proteins’ correlation and their clinical significance in colorectal cancerous tissues.
Results: The specimens were arranged into microarray using the immunohistochemistry method to investigate the
expression of integrin αvβ6 and transcriptional factor Ets-1 in these tissues. Among the 158 tissue specimens,
36.07% were positive for αvβ6 expression, and 57.59% were positive for Ets-1 expression. There were obvious
statistical differences existed regarding differentiation, N stage, M stage and TNM stage between αvβ6 and Ets-1
positively and negatively expressing tumors. The correlation analysis confirmed the expression of αvβ6 and Ets-1
were positively correlated in colorectal cancer. The Kaplan-Meier survival analysis showed that patients who were
both αvβ6 and Ets-1 positive relapsed earlier than those who were both αvβ6 and Ets-1 negative; and the former
group had much shorter survival time than the latter. And Cox model indicated that αvβ6 and Ets-1 were the
independent prognostic factors (RR = 2.175, P = 0.012 and RR = 3.903, P < 0.001).
Conclusions: The expression of αvβ6 and Ets-1 were positively correlated, and their expression degrees were
associated with the differentiation, N stage, M stage and TNM stage of the tumors. Hence, the combination of αvβ6
and Ets-1 can be used as a prognostic marker in colorectal cancer, especially for the early stage.Introduction
Colorectal Cancer (CCR) is the most frequent gastro-
intestinal malignant tumor in the world. According to
an estimate of International Agency for Research on
Cancer (IARC), there will be about 1.2 million new colo-
rectal patients all over the world every year, and the
mortality rate will account for about 8% of all malignan-
cies [1]. Generally, the CCR occurs more frequently in
developed countries. The number of CCR incidence and
mortality rates increased a lot in China in the past few
years [2]. From 2006 to 2009, the CCR became the 3rd
prevalent and 5th most malignant among the entire ma-
lignant tumor in China. Therefore, CCR seriously af-
fected the human health [3].* Correspondence: junniu120@163.com
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unless otherwise stated.αvβ6 is a special subtype of integrin that is expressed
in epithelial cells only, and its major ligand is fibronectin
(FN). In normal epithelial cells, the expression of αvβ6 is
rare and can hardly be detected [4], but it increases
substantially in response to injury and/or inflammation,
or in epithelial tumors [5]. Our previous studies show
that the de novo expression of the αvβ6 integrin has
been shown to modulate several processes in colon car-
cinoma cells, including cell adhesion and spreading on
fibronectin, proliferation within collagen gels, tumor
growth, cell apoptosis and matrix metalloproteinase
(MMPs) secretion [6,7]. We also have suggested that the
αvβ6 integrin is a prognostic indicator of gastric carcin-
oma, and αvβ6 would be a useful index to direct early
therapy in order to prevent the spread of cancer [8].
Ets-1 is a kind of transcription factor which is present
in species ranging from sponges to human. All family
members contain an approximately 85 amino acid DNA
binding domain, designated as the Ets domain. Ets-1td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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core motif of GGAA/T, and transcriptionally regulate in a
number of viral and cellular genes. Thus, Ets proteins are
an important family of transcription factors that control the
expression of genes which are critical for several biological
processes, including cellular proliferation, differentiation,
development, transformation, and angiogenesis [9-11].
Although, many studies have been conducted about find-
ing molecular markers as prognostic indicators for the ma-
lignant biological behavior of CCR; there is still a demand
to find indicators or its combinations regarding the CCR
development and progression. Since many papers have
shown that both integrin αvβ6 and transcription factor
Ets-1 participate in the regulation of malignant tumor bio-
logical behavior, therefore we performed the immunohis-
tochemical assessment of integrin αvβ6 and transcription
factor Ets-1. We expected these markers or their combi-
nations would become the prognostic indicators in CCR.
Results
Follow up
All the specimens can be used to assess the expression of
integrin αvβ6 and transcriptional factor Ets-1. 5-year
follow-up was conducted among all the 158 patients, and
the follow-up rate was 100%. Among these, 71 (44.9%)
were confirmed cancer specific death within 5 years of
prognosis and 87 (55.1%) were censored as their case fol-
low up was discontinued or patients were alive beyond
60 months or died of reasons other than colon cancer.115
patients (72.8%) relapsed from cancer during 5-year
follow-up, and 43 (27.2%) were censored. Follow-up based
on patient’s history, physical examination, complete blood
count, liver function tests, tumor markers monitoring,
ultrasound scan of the abdomen every 3 months, abdom-
inal pelvic CT scans and colonoscopy every 6 months.
Patients with high-risk factors were encouraged to take ad-
juvant chemotherapy. Patients with liver metastasis tumor
accepted the radiofrequency ablation (RFA) or super γ knife
radiotherapy. 87 patients received fluorouracil-based adju-
vant chemotherapy, and 28 patients received the RFA or
radiotherapy.
Expression of αvβ6 and Ets-1 in the tissue specimens and
clinical character
In the 158 tissue specimens, 57 (36.07%) were positive for
αvβ6 expression, and 91 (57.59%) were positive for Ets-1
expression. Clinicopathological features and αvβ6 & Ets-1
expression of all specimens were expounded in details in
Table 1. And the expression levels of αvβ6 and Ets-1 in 10
samples of normal colon mucosa were both negative. A
following analysis showed that there was no evidence of a
statistical difference between αvβ6 or Ets-1 positive and
negative tumors regarding age, gender, location, tumor
size, Duke’s phase, T stage, and histopathological type, butsignificant statistical differences existed regarding differen-
tiation, N stage, M stage and TNM stage. αvβ6 and Ets-
1staining patterns in the tissue specimens are shown in
Figure 1. High αvβ6 expression was detected at the invad-
ing edge of the tumor, and staining was observed predom-
inantly in the cell membrane. Ets-1 mainly exhibited a
nuclear and cytoplasmic immunostaining in tumor cells.
Correlation between the αvβ6 and Ets-1expression
In the 158 tissue specimens, 101 (63.92%) were nega-
tive for αvβ6 expression, 30 (18.99%) were low positive
for αvβ6 expression, 27 (17.09%) were high positive for
αvβ6 expression; 67 (42.41%) were negative for Ets-1
expression, 30 (37.34%) were low positive for Ets-1 ex-
pression, 32 (20.25%) were high positive for Ets-1 ex-
pression. The expression of αvβ6 and Ets-1 were
positively correlated (r = 0.711, P = 0.000), Specific data
was shown in Table 2.
Expression of both αvβ6 and Ets-1 predicts relapse and
patients survival
According to the expression of αvβ6 and Ets-1, all patients
were divided into four categories: both αvβ6 and Ets-1
positive group (Group 1), αvβ6 positive with Ets-1 nega-
tive group (Group 2), αvβ6 negative with Ets-1 positive
group (Group 3), and both αvβ6 and Ets-1 negative group
(Group 4), respectively. The Kaplan-Meier survival ana-
lysis showed that patients who were both αvβ6 and Ets-1
positive relapse earlier (32.59 ± 2.37) than those who were
in Group 2 (43.82 ± 2.57), Group 3 (46.68 ± 1.83), and
Group 4 (53.30 ± 1.10) (P = 0.000).And patients who were
in either αvβ6 or Ets-1 positive (Group 2 and 3) also
relapsed earlier than those who were both αvβ6 and
Ets-1 negative (P < 0.0001) (Figure 2). Likewise, the
Kaplan-Meier survival analysis showed that patients
who were both αvβ6 and Ets-1 negative live longer
(56.82 ± 0.95) than those who were both αvβ6 and Ets-
1 positive (46.23 ± 1.71), and those who were in Group
2 (52.31 ± 2.41) or Group 3 (53.62 ± 1.71) (P < 0.0001).
And patients who were in Group 2 or Group 3 live
shorter than those who were both αvβ6 and Ets-1
negative (P < 0.0001) (Figure 3).
Univariate and multivariate analysis for prognosis of
patients with colon cancer
The Cox proportional hazards regression model were
used to conduct Univariate and multivariate data analyses
to determine the prognostic value of αvβ6 and Ets-1 ex-
pression. Positive expression of αvβ6 and Ets-1, as well as
senior grade of N stage, M stage, and TNM stage were the
factors to predict a poor prognosis in univariate analysis
(Shown in Table 3). Then the variables with P < 0.05 were
chosen to conduct multivariate analysis, we revealed that
positive expression of αvβ6 and Ets-1 were unfavorable
Table 1 Patients characteristic and the expression of intgerin αvβ6 and transcriptional factor Ets-1
Factor N αvβ6 P Ets-1 P
Negative Low High Negative Low High
Age
<60 Y 62 34 16 12 27 23 12
>60 Y 96 67 14 15 0.127 40 36 20 0.964
Gender
Male 115 75 20 20 49 43 23
Female 43 26 10 7 0.705 18 16 9 0.991
Location
Colon 127 83 24 20 55 48 24
Rectum 31 18 6 7 0.641 12 11 8 0.688
Tumor size
<2 cm 15 9 4 2 6 6 3
2 ~ 5 cm 109 70 22 17 47 40 22
>5 cm 34 22 4 8 0.624 14 13 7 0.999
Differentiation
Well 28 22 4 2 15 9 4
Moderate 93 67 16 10 41 37 15
Poor 27 11 8 8 10 10 7
Unknown 10 1 2 7 0.000 1 3 6 0.035
Duke’s phase
A + B 92 59 20 13 40 34 18
C + D 66 42 10 14 0.366 27 25 14 0.942
T stage
T1 48 31 8 9 19 18 11
T2 70 42 16 12 28 30 12
T3 33 24 4 5 18 9 6
T4 7 4 2 1 0.851 2 2 3 0.470
N stage
N0 68 56 6 6 39 21 8
N1 67 33 18 16 22 28 17
N2 23 12 6 5 0.001 6 10 7 0.015
M stage
M0 130 93 24 13 60 52 18
M1 28 8 6 14 0.000 7 7 14 0.000
TNM stage
I&II 66 56 5 5 32 23 11
III 64 37 19 8 28 29 7
IV 28 8 6 14 0.000 7 7 14 0.000
Histopathological type
Tubular adenocarcinoma 134 85 26 23 58 52 24
Mucinous adenocarcinoma 15 10 2 3 6 4 5
Other type 9 6 2 1 0.955 3 3 3 0.826
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Figure 1 Images of αvβ6 and Ets-1 immunohistochemistry staining in human colorectal cancer samples. αvβ6 staining was observed
predominantly in the cell membrane. A-C the immunohistochemistry photomicrographs of integrin αvβ6. A: integrin αvβ6 weak staining, B:
integrin αvβ6 moderate stainning, C: integrin αvβ6 high staining; Ets-1 mainly exhibited a nuclear and cytoplasmic immunostaining in tumor cells.
D-F the immunohistochemistry photomicrographs of transcriptional factor Ets-1. D: Ets-1 weak staining, E: Ets-1 moderate staining, F: Ets-1
high staining.
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RR = 3.903, P < 0.001, respectively) (Shown in Table 3).
Discussion
Colorectal cancer has a higher morbidity and mortality






Negative 64 35 2
Low 2 19 9
High 1 5 21and treatments during the past years, the clinical out-
come of colon cancer remains unsatisfactory. Under-
standing the molecular mechanism of tumorigenesis
would contribute to treatment of patients with this dis-
ease [12].
The data in the present study indicated that the total
expression percentage of integrin αvβ6 and Ets-1 in
colorectal cancer was 36.07% and 57.59% respectively.
The expression level of αvβ6 and Ets-1 was associated
with the differentiation, N stage, M stage and TNM
stage of the tumors. Correlation analysis showed that
the expression of αvβ6 and Ets-1 were positively corre-
lated, and their strong stains were always detected at the
invading edge of the tumor, weak or no stain always in
the center of the tumor. These findings about integrin
Figure 2 Disease relapse time is also shown by Kaplane-Meier
survival analysis using a Log-rank test. The samples were
grouped according to αvβ6 and Ets-1 expression. (P = 0.000).
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gastric carcinoma [8], and Ets-1 expression pattern and
its role look like Ito [13]. The phenomenon above could
be explained as following: High cell density in tumor in-
duces integrin αvβ6 and Ets-1 expression, which pro-
mote MMP-9 secretion for colon cancer cells,increasingFigure 3 Patients survival time is shown by Kaplane-Meier
survival analysis using a Log-rank test. The samples were
grouped according to αvβ6 and Ets-1 expression. (P = 0.000).the degradation of extracellular matrix (ECM),which
constitutes the molecular biological basis for a self-
perpetuating system of tumor invasive growth in colon
cancer progression.
In the present study, survival analysis showed that pa-
tients who were both αvβ6 and Ets-1 positive relapsed
earlier than others, and their survival time was also obvi-
ously shorter. Based on these data, we confirmed that
the concomitant expression of αvβ6 and Ets-1 in colorec-
tal cancer cells could be used as an independent predictor
to determine early relapse, metastases and prognosis in
CRC patients. The important conclusion of this study is
similar with our previous study [14] and Zsuzsanna [15].
We have previously shown a direct linkage between
ERK2 and the cytoplasmic domain of β6, and have delin-
eated the binding domain for ERK2 within the cytoplasmic
tail of the β6-integrin subunit, 746EAERSKAKWQTGTN-
PLYRG764 (the ERK2 binding sequence is italic) [16].
Through this physical interaction, integrin αvβ6 trans-
mitted a growth-enhancing signal to cancer cells. In vivo
studies of colon cancer xenografts expressing a β6-
mutant lacking the ERK2 binding domain indicated that
deletion of the β6-ERK2 binding motif greatly compro-
mised tumor growth. Taken all the factors into consid-
eration, these results suggested that tumor growth was,
at least in part, dependent on direct αvβ6-ERK binding.
Meanwhile, we also have known that in colorectal can-
cer cells αvβ6-ERK2 direct linkage could increase the
phosphorylation level of ERK2, and ERK2 conformation
would be changed as soon as binding with αvβ6. To
some extent, this process helped ERK2 to be phosphory-
lated easily, and protected phosphorylated ERK2 not to
be dephosphorylated [17]. The effective targets of
phosphorylated-ERK2 were localized in the nucleus.
Unfortunately, the nuclear factors which could be regu-
lated by phosphorylated-ERK2 still remained unclear.
Park showed that the expression of Ets-1 has intim-
ate correlation with tumor cell invasion and metastasis.
Ets-1 and MMPs co-expressed in colon cancer and
other malignant tumor, and its expression degree
would be increased with tumor invasion and metastasis
extent accordingly, but its expression was very low
in benign and non-invasive tumor [18]. Hashiya
confirmed that Ets-1 played an important role in pro-
moting the tumor angiogenesis through regulating
angiogenesis factor, such as VEGF, Ang2, and so on
[11]. Other studies showed that Ets-1 could induce the
tumor cell apoptosis through regulating cell cycle via
changing the expression of p21, p53, cyclinD1, c-Fos in
tumor cells [19-21].
In this study, we confirmed that the αvβ6 and Ets-
1expressions were positively correlated, and they al-
ways expressed in invading edge of the tumor, and
their expression degree were associated with the
Table 3 Univariate and multivariate analysis of association of clinicopathologic features with survival time
Variable Univariate analysis Multivariate analysis
Relative risk 95% CI P value Relative risk 95% CI P value
Age at diagnosis 0.996 0.980,1.011 0.583
Gender
Male 1.000(Ref.) - -
Female 1.053 0.651,1,702 0.834
Location
Colon 1.000(Ref.) - -
Rectum 1.014 0.628,1.638 0.953
Tumor size 0.064
<2 cm 1.000(Ref.) - -
2 ~ 5 cm 0.592 0.282,1.245 0.167
>5 cm 1.356 0.798,2.302 0.260
Duke’s phase
A + B 1.000(Ref.) - -
C + D 1.460 0.877,2.432 0.146
T stage 0.386
T1 1.000(Ref.) - -
T2 1938.169 0.000,>10 5 0.912
T3 2612.435 0.000,>10 5 0.909
T4 3765.785 0.000,>10 5 0.905
N stage 0.010 0.721
N0 1.000(Ref.) - - 1.000(Ref.) - -
N1 2.202 1.302,3.727 0.003 0.697 0.261,1.859 0.470
N2 1.845 0.921,3.696 0.084 0.649 0.221,1.903 0.431
M stage
M0 1.000(Ref.) - - 1.000(Ref.) - -
M1 3.430 2.019,5.828 <0.001 1.998 0.432,9.235 0.376
TNM stage <0.001 0.709
I 1.000(Ref.) - - 1.000(Ref.) - -
II 1.421 0.427,4.734 0.567 1.599 0.479,5.341 0.446
III 2.697 0.804,9.049 0.108 1.846 0.384,8.887 0.444
IV 6.005 1.777,20.296 0.004 # # #
Differentiation 0.257
Well 1.000(Ref.) - - 1.000(Ref.) - -
Moderate 1.606 0.802,3.216 0.181
Poor/unknown 1.794 0.889,3.620 0.103
Ets-1
Negative 1.000(Ref.) - - 1.000(Ref.) - -
Positive 4.913 2.792,8.645 <0.001 3.903 1.945,7.832 <0.001
αvβ6
Negative 1.000(Ref.) - - 1.000(Ref.) - -
Positive 3.775 2.324,6.133 <0.001 2.175 1.190,3.974 0.012
#: TNM stage IV is linearly dependent on M stage M1.
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tumors. So we thought that Ets-1 was likely to be the
nuclear factor of ERK2. Perhaps, we proposed that in-
tegrin αvβ6 regulated the cancer cell malignant bio-
logical behavior through αvβ6—ERK—Ets-1 signal
pathway.
Importantly, Ets-1 could transcriptionally regulate the
expression of integrin beta6, which has been reported by
Bates et al. [22]. Thus, a signal loop involving Ets-1 and
αvβ6 probably exists to play a key role in tumor cellular
growth and migration. Of course, our hypotheses need
demonstrating in our future work.
We have already demonstrated that β6-integrin is as-
sociated with chemo resistance in colon cancer, and
β6-integrin could induce 5-FU resistance through the
ERK/MAP kinase pathway and the β6-ERK2 direct
binding [23]. In our another study, we have also proved
that Norcantharidin (NCTD), as an anti-cancer trad-
itional chinese medicine, could decrease αvβ6 expres-
sion and inhibit ERK phosphorylation in HT-29 cells
[24]. In the present study, we found combination of
αvβ6 and Ets-1 could favor colon cancer prognosis.
These results indicate β6-integrin might be a novel
therapeutic target in colon cancer therapy, and it
reminded us that if positive αvβ6 and Ets-1 were found
in patients with colon cancer of early stage, compared
with negative, we would take more aggressive chemo-
therapy, or more frequent reexamination. However, pa-
tients in advanced stage have a worse prognosis,
whatever aggressive therapy to take. Therefore, we
should take earlier diagnosis and treatment of cancer,
and different therapy methods could be applied in pa-
tients with distinct gene expression patterns.
To Date, based on this study results and other previ-
ous conclusions, we think that co-expression of αvβ6
and Ets-1 could serve as a significant prognositic indi-
cator for colorectal cancer, and their interaction might
play an important role in cancer progression. There-
fore, any key molecule in αvβ6—ERK—Ets-1 signal
pathway, or even the potential signal loop, can be used
as an attractive therapeutic candidate for CRC. This
new study is encouraging. However, further research is
needed to confirm the findings and to establish the re-
lationship between the αvβ6 and Ets-1 as a significant
prognositic indicator for colorectal cancer.
Materials and methods
Antibodies and reagents
The mouse anti-human monoclonal antibody 6.2A1
(IgG1) against integrin αvβ6 was obtained from Biogen
(Cambridge, USA), monoclonal antibody A0478 (IgG1)
against Ets-1 was obtained from Bio-tech (Sunnyvale,
California, USA), and biotinylated rabbit anti-mouse
IgG was obtained from Dako (Copenhagen, Denmark).Human tissue specimens
158 cases of colorectal carcinoma specimens and endo-
scopic colon biopsy samples of normal colon mucosa
(n = 10) which obtained from January 2006 to June
2008, were selected randomly from Qilu Hospital of
Shandong University (Jinan, Shandong Province, China).
Those colorectal carcinoma and normal colorectal mu-
cosa specimens were formalin-fixed and paraffin-
embedded. The informed consent was obtained from
all the patients or their relatives. The study complied
with the requirements of The Ethics Committee of
Qilu Hospital, Shandong University.
Immunohistochemistry
Immunohistochemistry was performed on 5 micrometer
sections of the FFPE routine sections and tissue micro-
array (TMA) analysis using monoclonal mouse antibodies
against αvβ6 (6.2A1) and Ets-1 (A0478) was applied re-
spectively. The sections were deparaffinized and hydrated,
and the heat induced epitope retrieval was performed
using Borg decloaking high pH buffer in the Biocare
decloaking chamber. Endogenous peroxidase’s activity was
blocked with 3% hydrogen peroxide. The slides were first
incubated with an avidin-biotin kit, followed by incuba-
tions with the αvβ6 primary antibody (1:500 dilutions)
overnight at 4°C, streptavidin-horseradish peroxidase, and
Betazoid Diaminobenzidine for color development. Nega-
tive controls were prepared by using the identical concen-
tration of mouse immunoglobulin IgG1 (Dako). The next
day, biotinylated anti-mouse IgG (1:200) was applied to
the slides, which were subsequently treated using horse-
radish peroxidase (HRP)-labelled streptoantibiotin (Dako)
for 15 min. The slides were counterstained with Dako
Hematoxylin, rinsed with water, and then dehydrated with
alcohol and xylene, and coverslipped. Appropriate con-
trols were included. All incubations were done at the
room temperature.
Assessment of αvβ6 and Ets-1 scoring in the tissue sections
αvβ6 stain was mainly on the internal surface of the
tumor cell membrane. αvβ6 and Ets-1 stain were evalu-
ated independently by two pathologists who were
blinded to patients’ prognosis. Disagreements were re-
solved by discussion in a meeting which was held to ob-
tain the final results. The proportion score represented
the estimated fraction of positive staining cells (0, 0%; 1,
<20%; 2, 20 ~ 50%; 3, 51 ~ 75%; 4, > 75%). Intensity of
the staining: 0, no staining; 1, weak staining, pale brown;
2, moderate staining, brown; 3, strong staining, dark
brown. We took into account both the intensity and the
proportion of positive cells to give a semi quantitative
estimate of the expression levels of antigen in the tissue
core. Added the two scores, the last score of every
section was obtained. We defined the staining class
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score < 2 were designated as negative expression, 2 ~ 4
as low (weak) expression, and ≥5 as high (strong) ex-
pression. Both low and high expressions were graded as
αvβ6 and Ets-1 positive.
Patients and follow-up
From January 2006 to June 2008, 158 patients who
underwent curative resection by the same surgical
team for pathologically confirmed colon cancer at the
Department of Pathology of Qilu Hospital (Shandong
University, China) were divided into three groups (both
αvβ6 and Ets-1 positive group, both αvβ6 and Ets-1
negative group, and either αvβ6 or Ets-1 positive group)
to investigate disease relapse and survival time. In our
protocol for the follow-ups, all patients were followed
every 3 months in the first year and at least every
6 months afterwards. They were examined with regular
monitoring of metastasis by abdomen ultrasonography
or computed tomography (CT) studies of the peritoneal
organs and lymph nodes. New relapse lesions were diag-
nosed based on the typical image findings from CT
scans.
Statistical methods
Associations between immunohistochemical scores and
clinicopathologic variables of tissue specimens were
evaluated by χ2 test. Expression correlation of αvβ6 and
Ets-1 was assessed using bivariate correlation analysis by
χ2 test. Disease relapse time was referred to as the time
from the date of surgery to colorectal cancer-related dis-
ease appearance, including local recurrence, liver metas-
tasis, peritoneal metastasis, significantly elevated tumor
markers, and etc. Survival time was measured as the time
from the date of surgery to disease-related death, and
those who died from other reasons or were still alive when
they were last seen were censored. Survival analysis was
carried out using the Kaplane-Meier survival and Cox
model analysis. P < 0.05 was considered statistically signifi-
cant. Graphs showed the mean ± SD of data from a repre-
sentative experiment; data were representative of at least
three experiments with comparable results.
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